Mesoblast completes dosing in Phase 3 back pain trial
Mesoblast Limited says it has concluded patient dosing for its Phase 3 MSB-DR004 trial of rexlemestrocel-L in chronic low back pain linked to inflammatory degenerative disc disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.